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Historically there has been a high rate of surgical interventions to obtain clear margins for breast cancer patients
undergoing breast conserving local therapy. An intraoperative margin assessment tool (MarginProbe) has been
approved for use in the US since 2013. This study is the first compilation of data from routine use of the device, to
assess the impact of device utilization on re-excision rates. We present a retrospective, observational, review from
groups of consecutive patients, before and after the implementation of intraoperative use of the device during
lumpectomy procedures. Lesions were localized by standard methods. The intraoperative margin assessment device
was used on all circumferential margins of the main specimen, but not on any additional shavings. A positive
reading by the device led to an additional shaving of the corresponding cavity location. Specimens were also,
when feasible, imaged intra-operatively by X-ray, and additional shavings were taken if needed based on clinical
assessment. For each surgeon, historical re-excision rates were established based on a consecutive set of patients
from a time period proximal to initiation of use of the device. From March 2013 to April 2014 the device was
routinely used by 4 surgeons in 3 centers. In total, 165 cases lumpectomy cases were performed. Positive margins
resulted in additional re-excision procedures in 9.7% (16/165) of the cases. The corresponding historical set from
2012 and 2013 consisted of 186 Lumpectomy cases, in which additional re-excision procedures were performed in
25.8% (48/186) of the cases. The reduction in the rate of re-excision procedures was significant 62% (P < 0.0001).
Use of an intraoperative margin assessment device contributes to achieving clear margins and reducing re-excision
procedures. As in some cases positive margins were found on shavings, future studies of interest may include an
analysis of the effect of using the device on the shavings intra-operatively.Background
Breast conservation surgery followed by radiation is the
recommended treatment (National Institute of Health
2014) for most early stage (I & II) breast cancer. From
recent reports, in the US a breast conserving approach
amounts to 60-75% of the procedures for treatment of
early stage breast cancer (Katipamula et al. 2009; Cancer
Trends Progress Report – 2011). This treatment approach
has been shown to be equivalent to treatment by mastec-
tomy (Veronesi et al. 2002; Fisher et al. 2002). With the
implementation of screening programs and the advance-
ment of diagnostic techniques, these constitute the major-
ity of diagnosed breast cancers.
Obtaining clear margins following a lumpectomy surgery
for breast cancer is an important factor in the treatment of* Correspondence: mls2663@virginiahospitalcenter.com
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in any medium, provided the original work is pbreast cancer while conserving the breast (BCS). This is
not a trivial task, and in many cases the margins are not
clear following the initial lumpectomy procedure, necessi-
tating a re-excision in order to achieve clear margins. From
population based studies the rates of re-excision proce-
dures in the US are reported to be approximately 25%
(McCahill et al. 2012; Morrow et al. 2009). There have
been numerous reports and discussions of the topic on
clear margins, including meta analyses (Houssami et al.
2010; Wang et al. 2012; Blair et al. 2009; Dunne et al.
2009). Recently, this topic has been the subject of an up-
dated SSO/ASTRO guideline (Moran et al. 2014).
MarginProbe (MP, by Dune Medical Devices, Paoli,
PA, USA) is a new device developed to identify cancerous
tissue at the margins of excised lumpectomy specimens.
The device is used intraoperatively, in real-time, enabling
immediate margin resection. The device measures the
local electrical properties of breast tissue, and provides a
positive/negative reading for each measurement (7 mmis an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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lumpectomy specimen. The device has been evaluated in
several multicenter trials, see review in (Thill et al. 2013),
where patients were randomized to standard of care tech-
niques for margin evaluation versus standard of care with
additional (adjunctive) use of MP. These studies have
shown that adjunctive use of MP leads to a > 50% reduc-
tion in the rate of re-excision procedures. These studies
also showed that the device integrates well with the OR
work flow, and that cosmetic outcomes were not affected.
MP performance is the same for the different cancer hist-
ology subgroups, including DCIS. MP has been approved
for use in the US since the beginning of 2013.
Here we provide the first report on routine use of MP
in 3 centers in the US. The effect on the rate of re-
excision procedures was based on comparison to histor-
ical records.Methods
Retrospective review observational (routine-data-based)
study at 3 centers, 4 surgeons, all using their routine
lumpectomy methods, both before, and after initiation of
use of MP. No standardization between surgeons was re-
quired. Criteria for re-excision were per surgeon/institu-
tion. MP was used on a routine basis, without any patient
selection criteria. All patients were recently diagnosed with
breast cancer.
Mammographic/Ultrasound findings were typically
histologically confirmed via biopsy. Lesions were, in gen-
eral, wire localized. Specimens were oriented and margin
borders were delineated. In accordance with general prac-
tice, standard Intra-operative assessment included palpa-
tion, x-ray, ultra-sound and gross pathology, whichever
was appropriate for a given patient. MarginProbe was used
as an adjunctive tool for intra-operative margin assess-
ment on the main lumpectomy specimen, following its
excision. All 6 faces/aspects were interrogated (exclud-
ing skin and fascia/muscle). Duration of use is 3 to 5 mi-
nutes. Additional shavings were taken based on device
readings. All specimens were processed by routine per-
manent pathology.Table 1 Device utilization




1 May-13 39 4.3
2 May-13 42 3.8
3 Nov-13 39 7.9
4 Mar-13 45 3.5
Total 165Data collection
Data was collected for the period from when each cen-
ter/surgeon started using the device up until April 2014.
Data was collected from operative notes, pathology re-
ports & hospital records. Data on device readings was
obtained from operative notes. Margins status was also
recorded for the main lumpectomy specimen. For each
center, historical data were obtained for time periods of
duration similar to that in which MP was used. Histor-
ical data were obtained from the years 2012 and 2013,
time periods proximal (shortly before) to the initiationof use of the device. As this was a retrospective review
observational study, there was no need for consent.
Statistical analysis
Numerical variables were tabulated using mean, stand-
ard deviation, and ranges. Categorical variables were tab-
ulated using number of observations and percent. All
statistics were performed at α = 0.05 two-sided signifi-
cance level. Rates between arms were compared using
Fisher’s exact test. No missing data was imputed.
Results
Up until April 2014 the device was used on a total 165
patients. Table 1 shows the break-down of patients per
surgeon, and the time at which each center started using
the device. The earliest being March 2013.
Table 2 describes patient baseline characteristics. The
distributions of age, tumor type histology, and receptor
status data are consistent with those reported in the
2011 SEER database (Howlader et al. 2014). Patients di-
agnosed with DCIS amounted to 20%, very similar to the
2011 SEER database value of 20.4%.
As seen in Table 3, most all patients were diagnosed
by core biopsy. Most lesions were localized pre-surgery,
consistent with them being early stage cancer patients.
Only 21% the patients had palpable tumors.
Tumor characteristics based on final pathology are
presented in Table 4. Average tumor size was 1.5 (+/-
1.1) cm, with the majority of the lesions (76%) less than
2 cm in size. In the majority of the invasive tumors, 59%
(77/131) the tumor had a DCIS component. Overall,
there was DCIS present in 67% of tumors.
For 127 of the cases pre-operative tumor type com-
position was available (in the operative notes and/or
pathology reports). These data are presented in Table 5.
Pre-operatively, the tumor composition was invasive,
with no DCIS component, in 50% (64/125) of the cases.
For these, when comparing to final pathology, in 56%
(36/64) of the cases a DCIS component was identified
on final pathology. Out of the 34 cases pre-diagnosed as
DCIS, 15% (5/34) were upstaged to Invasive cancer on
final pathology.
To evaluate the contribution of MP in reducing the
rate of re-excision procedures, the re-excision rates with
Table 2 Patient demographics
Age
Mean (STD) 60.5 (12.4)
<40 5 3%
40 to 50 30 18%
50 to 60 46 28%
60 to 70 44 27%
>70 39 24%
Tumor type
Invasive Ductal 119 72%
Invasive Lobular 12 7%
DCIS 33 20%
Other (Sarcoma met) 1 1%
Receptor status Pos Neg % Pos
ER 99 12 89%
PR 84 27 76%
HER2 15 89 14%




IDC + DCIS 75 45.5%
ILC 11 6.7%
ILC + DCIS 1 0.6%
IPC 2 1.2%
ITC 4 2.4%
ITC + DCIS 1 0.6%
PCIS 1 0.6%











Mean (STD) 1.5 (1.1)
<1 51 35%
1 to 2 58 40%
>2 35 24%
IDC: Invasive Ductal Carcinoma; ILC: Invasive Lobular Carcinoma; DCIS: Ductal
Carcinoma In-situ; IPC: Invasive Papillary Carcinoma; ITC: Invasive Tubular
Carcinoma; PCIS: Papillary Carcinoma In-situ.
Table 5 Comparison to pre-operative tumor type
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historical set. For each surgeon, the historical set consisted
of a consecutive series of cases from a time period shortly
before she started using MP. The set was from a duration
of time similar to that for which MP was in use, ensuring
that the fraction of cases (for each surgeon) in the histor-
ical set will be distributed between surgeons in the same
manner as the cases in which MP was used. As seen in
Table 6, the total number of cases in the historical set and
the number of cases per surgeon are similar to those
where MP was used.
The numbers and rates of re-excision procedures are
also presented in Table 6, both for the MP cases and
the historical set. With use of MP, in 9.7% (16/165) of
the cases there was a re-excision procedure performed. In
the historical set, in 25.8% (48/186) of the cases there was
a re-excision procedure performed. The relative reduction
in the rate of re-excision procedures was 61%, with the
corresponding absolute reduction being 16.1%. The reduc-
tion was highly statistically significant, P < 0.0001.Table 3 Pre-operative
Pre-operative diagnosis by:
core biopsy 163 98.8%
open biopsy 1 0.6%
no biopsy 1 0.6%
Lesion localization:
Needle Localization (FNL) 127 77%
Ultrasound clip 4 2%
None (palpable) 34 21%As is also seen from Table 6, the reduction was similar
across surgeons. The re-excision rates for the historical
set varied by more than a factor of 3, spanning from
12% to 44%. The per surgeon relative reduction in the
re-excision rates was between 51% and 66%. The re-
excision rates with use of MP were between 4% and 17%.composition diagnosis
IDC 64 50%





Based on final path
DCIS added 36 56%
Upstage to Invasive 5 15%
Table 6 Historical control/set comparison of re-excision procedures
Total Per Surgeon
1 2 3 4
MarginProbe Procedures Lumpectomy procedures 165 39 42 39 45
Re-excision procedures 16 3 7 4 2
Re-excision rate 9.7% 8% 17% 10% 4%
Historical Lumpectomy procedures 186 51 48 46 41
Re-excision procedures 48 8 21 14 5
Re-excision rate 25.8% 16% 44% 30% 12%
Reduction Absolute Reduction (% points) 16.1% 8.0% 23.8% 20.2% 7.8%
Relative reduction 62% 51% 62% 66% 64%
P-value <0.0001
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standardized between surgeons.
Re-excision procedures are performed due to insuffi-
cient margin clearance based on final pathology. As the
device was used only on the main specimen, it could
only contribute to the identification of margins on the
initial lumpectomy specimen. As a result, in some cases,
even though there were shavings taken, the margins of
the shavings themselves remained persistently involved,
leading to a re-excision procedure. From Table 7, out of
the total re-excision procedure rate of 9.7%, 6.1% (10/
165) of the re-excision procedures were due to failed de-
tection of margins on main specimen. The remaining
3.6% (6/165) were due to involved margins on shavings.
An additional situation may occur when there was an
underestimation of the extent of the disease pre-surgery.
As presented in Table 7, there were 1.8% (3/165) cases
in which mastectomy was performed as a second pro-
cedure; this being due to the identification on final path-
ology of extensive disease with insufficient margin
clearance. Cancer was also present within the shavings
taken.
Discussion
Surgical treatment of breast cancer while conserving the
breast is a recommended, and well accepted approach for
the treatment of early stage (stage I & II) breast cancer.
Associated with this approach is the need to perform re-
excision procedures in order to achieve negative margins.
A significant fraction of the women treated by breast
conserving surgery will undergo additional surgeries toTable 7 Break-down of additional surgical procedures
Re-Excision Lumpectomy procedures 9.7% (16/165)
Due to failed detection of margins on main specimen 6.1% (10/165)
Due to margins on shavings 3.6% (6/165)
Mastectomy as a second procedure (due to
extensive disease)
1.8% (3/165)achieve clear margins. Intraoperative assessment of the
lumpectomy specimen is routinely performed, but stand-
ard techniques such as palpation and specimen imaging
(by radiography and/or ultrasound), are not able to dis-
cern microscopically residual disease at the margins. This
limitation is more pronounced in the case of non-palpable
lesions and DCIS (Balch et al. 2005; Jeevan et al. 2012). In-
traoperative margin assessment with specimen imaging
and immediate pathologic analysis (Cabioglu et al. 2005)
and immediate excision of any margins thought to be
close or positive can reduce the need for a return to the
operating room. This approach requires close coordin-
ation between surgery, pathology, and diagnostic radi-
ology and may not be possible to implement in all
practice settings.
The MP device provides real-time intraoperative assess-
ment of microscopic lumpectomy margins. Published re-
ports on use of the device have so far been in the settings
of clinical studies. In this retrospective case review, we pro-
vided the first report on routine use of the device in the
USA. The device integrated very well with the workflow in
the operating room, taking no more than 5 minutes to use.
There were no adverse events associated with device use.
Adjunctive use of the device significantly decreases, when
compared to corresponding historical series, by 62% the
rate of patients who required re-excision procedures. The
margin thresholds for returning a patient to the operating
room were not standardized between surgeons. Still, this
relative reduction was similar irrespective of the nominal
rates per surgeon. With use of the device, the rate of re-
excision procedures was 9.7%.
Most all of the patients in this contemporary consecu-
tive series were early stage breast cancer patients, with
79% of the malignant lesions localized prior to surgery.
The majority of the tumors (67%) included an intra-ductal
(DCIS) component. Additionally, there was a significant
number of cases where DCIS was only identified post-
surgery. This contributes to the challenge the surgeon
faces with regards to margins.
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malignant lesion(s) intra-operatively may also assist in
identifying extensive disease that was not picked up dur-
ing the cancer diagnosis. There were 3 patients in which
extensive disease (within the shavings as well) was iden-
tified, who proceeded directly to mastectomies.
There is no complete correlation between positive
margins status and the presence of cancer during re-
excision procedures (Skripenova & Layfield 2010; Scopa
et al. 2006). With use of the device there were 28 cases
in which the margin on the main specimen was clear,
but the corresponding shaving taken contained cancer.
These correspond to disease that would not have been
identified during final pathology, had not the shavings
been taken. This may reflect the presence of discontinues
disease, or may be due to the sampling limitation inherent
to the histopathology processing methods.
The topic of what constitute a clear margin has long
been under debate. Lately, there have been renewed dis-
cussions related to this topic (Houssami et al. 2014; Jagsi
et al. 2014; Hunt & Sahin 2014; Buchholz et al. 2014;
Hunt et al. 2014). Specifically, the new SSO guidelines
(Moran et al. 2014) suggest using tumor on ink (tumor
cells at the cut surface) as the definition for positive mar-
gin. In view of this, we also looked at the contribution of
device in identification of positive margins on ink. In 18%
(30/165) of the cases the primary (main) lumpectomy spe-
cimen, prior to intra-operative assessment, had tumor on
ink. In 73% (22/30) of these cases with use of device the
positive margins were identified. In 3.6% (6/165) of the
cases re-excision procedures were performed due to mar-
gins on ink. Of these, only 2.4% (4/165) were due to failed
detection of tumor cells at the margins.
Re-excision procedures also represent a significant bur-
den to the medical system. According to the National
Cancer Institute, in 2008, 60% of women age 20 and
older diagnosed with early-stage breast cancer under-
went breast-conserving surgery (Cancer Trends Pro-
gress Report – 2011). According to American Cancer
Society, 296980 cases of female breast cancer, both inva-
sive and DCIS, were diagnosed in 2013 (American Cancer
Society 2013). If 60% of these patients underwent breast
conserving procedures, there would be 178188 lumpec-
tomy procedures performed. A re-excision rate of 25%
would translate to 44547 re-excision procedures. Utilizing
the MarginProbe could decrease the re-excision rate by
62%, resulting in 27612 fewer of these surgeries. There
would be significant savings to the health care system
resulting from this decrease in the re-excision rate, and
the burden to the patient would be reduced.
The inability to achieve acceptable lumpectomy mar-
gins with one operative procedure, has multiple negative
effects. It increases the burden to the patient, who is
subject to the inconvenience, discomfort and heightenedanxiety of the unexpected second procedure and the loss
of productive time from work and family. Additional
surgeries carry an added risk of complication and nega-
tively impact cosmetic outcomes (Heil et al. 2012). The
necessity for additional surgery may also lead to a delay
in the initiation of other required therapies.
The fear and uncertainty generated by the potential
need for a re-excision procedure may be related to the
recent increase (King et al. 2011) in the proportion of
patients with early stage breast cancer opting for mastec-
tomy. Additionally, in some cases, patients “refuse” the rec-
ommendation for a re-excision procedure, putting them in
a higher risk for in breast reoccurrence.
The device was used on the lumpectomy specimen,
but not on additional shavings taken. About a third (6/16)
of the re-excision procedures were due to the shavings be-
ing positive. It would be interesting to investigate how to
incorporate device use on the shavings as well.
Utilization of techniques for partial breast irradiation
and intraoperative breast irradiation (Vaidya et al. 2010)
are also negatively impacted by re-excision procedures.
The importance of obtaining clear margins is elevated
when performing Onco-plasitc procedures during the ini-
tial lumpectomy surgery, as it may not be as clear where
additional tissue should be removed. And the additional
surgery could negatively impact the cosmetic result.
Conclusions
This report on routine use of MarginProbe provides
additional support for use of the device. Use of the de-
vice was associated with a significant decrease in the
rate of re-excision procedures. This provides the sur-
geons with added confidence when performing lumpec-
tomy surgery, reduces the burden for the health care
system, and increases the assurance of patients in this
surgical treatment approach for breast cancer.
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